Accelerating ADCs’ development pipeline using Simcyp PBPK
With nearly 10 million deaths in 2020 and despite great progress, cancer remains the leading…
CertaraOctober 15, 2021
PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib
Cobimetinib (Cotellic®), approved by the US FDA in 2015, is a kinase inhibitor for treating…
CertaraAugust 12, 2021
DDI Regulatory Poster Child using the Simcyp Simulator: Ibrutinib (Imbruvica®)
Pharmacylics and J&J sought to bring ibrutinib, its new tyrosine kinase inhibitor therapy targeting rare…
CertaraJuly 29, 2021
Key Considerations to Ensure Maximal Probability of Antibody Drug Conjugate Development Success
Antibody drug conjugates (ADC) are a unique way to obliterate tumor cells and represent an…
CertaraJuly 8, 2021
Strengths and opportunities for HTAs and market access in Europe through case studies
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
CertaraMay 26, 2021
Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology
Bispecific antibodies (bsAbs) have become an integral component of the therapeutic research strategy to treat…
CertaraJuly 14, 2020
Optimize Immuno-oncology Drug Discovery and Development Using QSP
A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…
CertaraJune 19, 2019
